AngioDynamics (NSDQ:ANGO) said today it won CE Mark approval in the European Union for its Solero microwave tissue ablation system, with indications for ablation of soft tissue during open, laparoscopic or percutaneous procedures.
The Albany, N.Y.-based company’s Solero MTA system features a 2.45GHz microwave generator with an operating frequency up to 140 watts and a ceramic tip designed to diffuse microwave energy spherically, with a patented cooling channel to help protect non-targeted tissue ablation.
“The Solero microwave tissue ablation system is a significant addition to our portfolio of oncology/surgery products and allows physicians to maximize the volume of tissue ablated in the shortest period of time. Solero is a single applicator system able to complete up to a 5 cm ablation in 6 minutes at maximum power,” oncology & surgery division GM Rick Stark said in a press release.
AngioDynamics said that the device is not intended for use in cardiac procedures.
In January, AngioDynamics saw shares rise after the medical device maker met expectations on Wall Street with its fiscal 2nd quarter results.
The company posted profits of $45 million, or 37¢ per share, on sales of $89 million for the 3 months ended Nov. 30, for bottom-line loss of -2% on sales loss of -0.3% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were 37¢, ahead of consensus on The Street, where analysts were looking for sales of $91.9 million.